stephen Allan noted, does not preclude Unilife from partnering with other companies in the area of severe hypoglycemia treatment, only from partnering with companies that wish to develop identical versions of Biodel's platform.
I was wondering how the dominant players were going to respond it essentially means that the two big players in this market lilly and novo nordisc can still slig it out to get ezy mix
Add to My Watchlist
What is My Watchlist?